Skip to main content
. 2014 Sep 17;40(3):601–613. doi: 10.1038/npp.2014.207

Figure 5.

Figure 5

Effect of blonanserin on Thr197-phosphorylated PKA and Ser897- or Ser896-phosphorylated NR1 in the medial prefrontal cortex (mPFC) of PCP-administered mice. PCP-administered mice were treated with SCH23390 (0.02 mg/kg, s.c.) and blonanserin (3 mg/kg, p.o.) for 60 and 30 min, respectively, before the NORT training session. Immediately after the training trial, mice were decapitated, and then Thr197-phosphorylated PKA (a) or NR1 (c, Ser897; d, Ser896), and total PKA (b) or NR1 (e) expression in the mPFC were determined by western blotting analysis. Representative western blot and phosphorylated PKA/total PKA or phosphorylated NR1/total NR1 immunoreactivity in the mPFC. Values indicate the mean±SEM (n=5–9). One-way ANOVA: PKA: F3, 32=4.046, p<0.01, (a); NR1 Ser897: F3, 19=4.046, p<0.05, (c). *p<0.05 compared with mice receiving (Sal/Veh/Veh); #p<0.05, ##p<0.01 compared with mice receiving (PCP/Veh/Veh); $$p<0.01 compared with mice receiving (PCP/BNS/Veh) (Fisher's PLSD test). BNS, blonanserin; PCP, phencyclidine; Sal, saline; SCH, SCH23390; Veh, vehicle.